The Department for Health and Social Care has asked NICE to conduct an appraisal of venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable.
Please note that following on from a request from the company, the timelines for this appraisal have been revised and technical engagement is now anticipated to begin in mid June 2021.